Vutiglabridin not checked

Glaceum · HSG4112

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
7 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Knee Osteoarthritis (Knee OA)
Main trialPhase 2
“1. Study Objective To Explore the Efficacy and Evaluate the Safety of Vutiglabridin in Knee Osteoarthritis Patients 2. Background Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of vutiglabridin in healthy subjects through its Phase 1 trials, and is planning to perform this Phase 2a trial to assess the efficacy and safety of vutiglabridin in Knee Osteoarthritis Patients 3. Study Design and Protocol This study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based…”In the company’s words, NCT06845553 on ClinicalTrials.gov
Other names
HSG4112

Other drugs for Knee Osteoarthritis (Knee OA)

All 34 drugs for Knee Osteoarthritis (Knee OA)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Jul 2026 A Study to Assess the Efficacy and Safety of Vutiglabridin in Knee Osteoarthritis Patients
Phase 2Completed 31 Dec 2022 A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients
Phase 2Completed 16 Dec 2025 A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
Phase 1Completed 10 Feb 2021 A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112
Phase 1Completed 24 May 2021 A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112
Phase 1Completed 20 Jan 2022 A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112
Phase 1Completed 12 Dec 2022 A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Vutiglabridin

Following is part of Solo: you see every change to Vutiglabridin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in